A new trading day began on Monday, with Fulcrum Therapeutics Inc (NASDAQ: FULC) stock price down -4.58% from the previous day of trading, before settling in for the closing price of $4.37. FULC’s price has ranged from $2.86 to $13.70 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -1.37% over the past five years. Meanwhile, its annual earnings per share averaged 90.67%. With a float of $45.46 million, this company’s outstanding shares have now reached $53.94 million.
Let’s look at the performance matrix of the company that is accounted for 76 employees. In terms of profitability, gross margin is 77.44%, operating margin of -37.66%, and the pretax margin is -22.15%.
Fulcrum Therapeutics Inc (FULC) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Fulcrum Therapeutics Inc is 15.71%, while institutional ownership is 91.76%. The most recent insider transaction that took place on May 07 ’24, was worth 1,831. In this transaction Principal Accounting Officer of this company sold 236 shares at a rate of $7.76, taking the stock ownership to the 11,571 shares. Before that another transaction happened on Mar 08 ’24, when Company’s Vice President, Finance sold 4,884 for $11.72, making the entire transaction worth $57,219. This insider now owns 11,807 shares in total.
Fulcrum Therapeutics Inc (FULC) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.27 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 90.67% per share during the next fiscal year.
Fulcrum Therapeutics Inc (NASDAQ: FULC) Trading Performance Indicators
Here are Fulcrum Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 18.44. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.78.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.31, a number that is poised to hit -0.28 in the next quarter and is forecasted to reach -1.05 in one year’s time.
Technical Analysis of Fulcrum Therapeutics Inc (FULC)
Fulcrum Therapeutics Inc (NASDAQ: FULC) saw its 5-day average volume 0.65 million, a positive change from its year-to-date volume of 0.61 million. As of the previous 9 days, the stock’s Stochastic %D was 14.60%. Additionally, its Average True Range was 0.36.
During the past 100 days, Fulcrum Therapeutics Inc’s (FULC) raw stochastic average was set at 18.61%, which indicates a significant decrease from 19.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.83% in the past 14 days, which was lower than the 167.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.91, while its 200-day Moving Average is $6.20. Nevertheless, the first resistance level for the watch stands at $4.37 in the near term. At $4.57, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.79. If the price goes on to break the first support level at $3.95, it is likely to go to the next support level at $3.73. The third support level lies at $3.53 if the price breaches the second support level.
Fulcrum Therapeutics Inc (NASDAQ: FULC) Key Stats
With a market capitalization of 224.92 million, the company has a total of 53,939K Shares Outstanding. Currently, annual sales are 2,810 K while annual income is -97,340 K. The company’s previous quarter sales were 80,000 K while its latest quarter income was 55,410 K.
